Abstract
GLP-1 receptor agonists have transformed metabolic care, yet their influence extends far beyond direct human health. Appetite-suppressing drugs alter not only how people eat, but also how societies impact food production and resulting greenhouse gas emissions, land and water use, and nutrient pollution. We explore the potential environmental benefits of population uptake of these drugs and contend that planning a sustainable future requires accounting for the ecological outcomes driven by advances in medicine.